Arrowhead Pharmaceuticals, Inc. (ARWR) EPS Estimated At $-0.15

January 22, 2018 - By Henry Gaston

 Arrowhead Pharmaceuticals, Inc. (ARWR) EPS Estimated At $ 0.15

Analysts expect Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) to report $-0.15 EPS on February, 5.They anticipate $0.02 EPS change or 11.76 % from last quarter’s $-0.17 EPS. After having $-0.14 EPS previously, Arrowhead Pharmaceuticals, Inc.’s analysts see 7.14 % EPS growth. The stock increased 9.97% or $0.57 during the last trading session, reaching $6.29. About 4.72 million shares traded or 218.86% up from the average. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has declined 67.27% since January 22, 2017 and is downtrending. It has underperformed by 83.97% the S&P500.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Coverage

Among 8 analysts covering Arrowhead Research Corp (NASDAQ:ARWR), 3 have Buy rating, 0 Sell and 5 Hold. Therefore 38% are positive. Arrowhead Research Corp had 20 analyst reports since August 5, 2015 according to SRatingsIntel. Jefferies maintained Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) rating on Monday, June 26. Jefferies has “Hold” rating and $200 target. The stock has “Overweight” rating by Piper Jaffray on Friday, September 25. The firm has “Neutral” rating given on Wednesday, November 30 by Piper Jaffray. The rating was downgraded by William Blair to “Mkt Perform” on Wednesday, November 30. The rating was maintained by Jefferies on Thursday, August 3 with “Hold”. The rating was maintained by Chardan Capital Markets on Thursday, November 10 with “Buy”. The firm earned “Hold” rating on Monday, September 25 by Cantor Fitzgerald. The firm earned “Overweight” rating on Monday, November 27 by PiperJaffray. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) earned “Buy” rating by Cantor Fitzgerald on Friday, August 19. The firm has “Hold” rating by Piper Jaffray given on Thursday, September 14.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company has market cap of $533.30 million. The Company’s pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. It currently has negative earnings. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.

More notable recent Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news were published by: Businesswire.com which released: “Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock” on January 17, 2018, also Streetinsider.com with their article: “Arrowhead Pharmaceuticals Corp (ARWR) Prices 10M Common Stock Offering at $5 …” published on January 18, 2018, Fool.com published: “Here’s Why Arrowhead Pharmaceuticals Inc. Is Up Today” on January 11, 2018. More interesting news about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) were released by: Businesswire.com and their article: “Arrowhead Pharmaceuticals Appoints William Waddill to Board of Directors” published on December 27, 2017 as well as Streetinsider.com‘s news article titled: “Arrowhead Pharmaceuticals Corp (ARWR) Proposed Underwritten Offering of Common …” with publication date: January 17, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: